Patient-reported outcomes among omalizumab and salmeterol/fluticasone combination therapy patients

Journal of Asthma

Volumn 46, Issue 2, 2009, Pages 179-185

  Miller, Dave P ^a   Tom, Gladys ^a   Rasouliyan, Lawrence ^a   Chipps, Bradley ^b  

^a ICON CLINICAL RESEARCH   (United States)

^b Capital Allergy and Respiratory Disease Center   (United States)

Author keywords

Asthma; Fluticasone; Omalizumab; Productivity; Salmeterol

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; IMMUNOGLOBULIN E; OMALIZUMAB; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; DRUG DERIVATIVE; FLUTICASONE SALMETEROL COMBINATION; FLUTICASONE-SALMETEROL COMBINATION; MONOCLONAL ANTIBODY; SALBUTAMOL;

ADULT; ALLERGIC ASTHMA; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG MEGADOSE; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL PERFORMANCE; PRODUCTIVITY; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK; SCORING SYSTEM; SLEEP; SLEEP DISORDER; TREATMENT OUTCOME; WORK CAPACITY; ASTHMA; CLINICAL TRIAL; INTERNET; LEISURE; MIDDLE AGED; PATIENT SATISFACTION;

ACTIVITIES OF DAILY LIVING; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; EFFICIENCY; FEMALE; HUMANS; INTERNET; LEISURE ACTIVITIES; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 63149097936     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900802604103     Document Type: Article

References (22)

1. Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100:1139-1151. (Pubitemid 43793051)
2. American Lung Association Epidemiology and Statistics Unit Research and Program Services. Trends in Asthma Morbidity and Mortality: July 2006. Available at. http://www.lungusa.org/atf/cf/%7B7A8D42C2-FCCA-4604-8ADE-7F5D5E762256%7D/ ASTHMA06FINAL.PDF. Accessed May 28,2008.
3. American Academy of Allergy Asthma and Immunology. Asthma Statistics. Available at: http://www.aaaai.org/media/resources/media kit/asthma statistics.stm. Accessed May 28, 2008.
4. Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody.Med Gen Med 2005; 7:27.
5. 2-agonists: improved clinical efficacy and dosing options in patients with asthma. J Asthma 2005; 42:715-724. (Pubitemid 41759185)
6. Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003; 21:951-989. (Pubitemid 37222569)
7. 2-agonists be prescribed as initial maintenance treatment for asthma? CMAJ 2002; 167:1008-1009. (Pubitemid 36158652)
8. Niebauer K, Dewilde S, Fox-Rushby J, Revicki DA. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 2006; 96:316-326. (Pubitemid 43277171)
9. National Asthma Education and Prevention Program. Expert panel report: Guidelines for the diagnosis and management of asthma. Update on Selected Topics 2002. Bethesda,MD:US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2003. 02-5047:1-149.
10. Chipps B, Buhl R, Beeh KM, Fox H, Thomas K, Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 2006;22:2201-2208. (Pubitemid 44789985)
11. National Asthma Education and Prevention Program Expert Panel, Guidelines for the Diagnosis and Management of Asthma. 1997, National Heart, Lung, and Blood Institute, National Institute of Health.
12. Jonkers RE, van der Zee JS. Anti-IgE and other new immunomodulationbased therapies for allergic asthma. Neth J Med 2005; 63:121-128. (Pubitemid 40561526)
13. Physicians Desk Reference. Montvale, NJ: Medical Economics, 2002.
14. Davis LA. Omalizumab: a novel therapy for allergic asthma. Ann Pharmacother 2004; 38:1236-1242. (Pubitemid 38802169)
15. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med 2006; 100:1907-1917.
16. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988; 41:313-321. (Pubitemid 18089231)
17. Chen H. Assessing productivity impairment in patients with severe or difficult-to-treat asthma: validation of the Work Productivity Activity Impairment-Asthma questionnaire. J Allergy Clin Immunol 2006, 117(2):S181
18. Katz PP,Yelin EH, Eisner MD, Earnest G, Blanc PD. Performance of valued life activities reflected asthma-specific quality of life more than general physical function. J Clin Epidemiol 2004; 57:259-267. (Pubitemid 38456877)
19. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65. (Pubitemid 38096162)
20. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757-763. (Pubitemid 27446562)
21. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. JASA 1984; 79:516-524.
22. National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. NIH Publication No. 07-4051.